Cancer Drug Price Hike Demand Grows for 50% Rise in India

Cancer drug price hike is back in focus as Indian pharmaceutical companies have sought a sharp increase in prices of key chemotherapy medicines, citing a surge in platinum costs that is hurting production viability.

The cancer drug price hike demand comes as manufacturers warn that current price caps no longer reflect raw material realities, putting supply at risk.

Leading drug makers producing essential chemotherapy drugs such as carboplatin, cisplatin, and oxaliplatin have approached the National Pharmaceutical Pricing Authority (NPPA) seeking up to a 50% increase in ceiling prices.

These medicines are widely used in first-line cancer treatment and are considered critical for affordable oncology care in India. The demand is driven by a steep rise in platinum prices, a core ingredient in these drugs, which has nearly doubled in recent months.

Also Read: Advancing Interventional Radiology in India Through Collaboration

Manufacturers say the sudden spike has made production financially unsustainable under existing regulated pricing. While prices of these drugs have seen minimal revisions over the years, input costs have risen sharply, squeezing margins.

Companies have warned that if pricing is not corrected, it could lead to reduced manufacturing or even supply disruptions. This raises concerns about access to affordable cancer treatment, especially for patients who rely on these older, cost-effective therapies.

The government now faces a difficult choice between maintaining affordability and ensuring consistent supply. A price revision could ease pressure on manufacturers but may increase treatment costs for patients. On the other hand, delaying action could risk shortages of essential cancer medicines.

The issue highlights a growing challenge in the pharma industry—balancing drug price regulation with volatile raw material costs in life-saving treatments.